|
| Human VEGF165 Protein (LTP11118) |
|
| LTP11118 |
|
| 100ug |
|
|
$429 In stock |
| Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis. |
| Recombinant Human VEGF165 Protein is expressed from Expi293 without tag. It contains Ala27-Arg191. |
|
| VEGF165 |
|
| Human |
|
| P15692-4 |
|
| Ala27-Arg191 |
|
| The protein has a predicted MW of 19.2 kDa. Due to glycosylation, the protein migrates to 20-30 kDa based on the Tris-Bis PAGE result. |
|
| Immobilized Human VEGF165 at 1ug/ml (100ul/well) on the plate. Dose response curve for Biotinylated Human VEGFR1, His Tag with the EC50 of 26.9ng/ml determined by ELISA (QC Test). See testing image for detail. |
|
| No Tag |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
